BioCentury
ARTICLE | Company News

Ultragenyx's Mepsevii gets European approval

August 27, 2018 8:05 PM UTC

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said the European Commission approved an MAA for Mepsevii vestronidase alfa to treat mucopolysaccharidosis VII (MPS VII; Sly syndrome). The biotech said the drug is the first approved in Europe for the indication.

Ultragenyx CEO Emil Kakkis told BioCentury that the company expects the European pricing will mirror the U.S, where the drug has an average net annual cost of $375,000 per patient per year for a 25-kg patient. The company has not yet set a European launch date...

BCIQ Company Profiles

Ultragenyx Pharmaceutical Inc.